Want to join the conversation?
$MYL's Meda acquisition is expected to deliver estimated growth through 2018 of about 3% in revenues and about 5% in adjusted EBITDA. On a 2015 combined basis, the company will go from having two-thirds of the revenue from Generics and Specialty business will represent more than a third of the business.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.